Janus Henderson Group PLC Has $130,000 Stock Position in Savara Inc (NASDAQ:SVRA)

Janus Henderson Group PLC lowered its position in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 82.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,400 shares of the company's stock after selling 203,400 shares during the quarter. Janus Henderson Group PLC's holdings in Savara were worth $130,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Cibc World Markets Corp purchased a new position in Savara during the 4th quarter worth approximately $33,000. XTX Topco Ltd purchased a new position in shares of Savara during the fourth quarter valued at $34,000. Ameriprise Financial Inc. acquired a new position in Savara during the fourth quarter valued at $37,000. KLP Kapitalforvaltning AS purchased a new stake in Savara in the 4th quarter worth about $41,000. Finally, Hsbc Holdings PLC acquired a new stake in Savara during the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Stock Up 2.0%

Shares of SVRA traded up $0.04 during mid-day trading on Friday, hitting $2.28. 395,701 shares of the company's stock were exchanged, compared to its average volume of 1,241,447. The stock has a market cap of $394.76 million, a price-to-earnings ratio of -5.31 and a beta of 0.44. The firm has a fifty day moving average of $2.93 and a two-hundred day moving average of $2.96. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a twelve month low of $1.89 and a twelve month high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). On average, sell-side analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on SVRA shares. Wells Fargo & Company dropped their target price on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday. Evercore ISI lowered their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday. HC Wainwright downgraded shares of Savara from a "buy" rating to a "neutral" rating and cut their target price for the stock from $6.00 to $2.00 in a research report on Thursday. Finally, Guggenheim restated a "buy" rating and set a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $7.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.